Navigation Links
Gentium's Defibrotide Highlighted in Two Poster Presentations at,American Association for Cancer Research Annual Meeting

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 13, 2007 - Gentium, S.p.A. (NASDAQ:GENT) (the "Company") today reported that its lead investigational product, Defibrotide, will be the subject of two poster presentations at the American Association for Cancer Research's (AACR) Annual Meeting being held at the Los Angeles Conference Center in Los Angeles, California, from April 14-18, 2007.

On Monday, April 16, 2007, from 1:00 p.m. to 5:00 p.m. (Pacific Time), Dr. Cinara Echart, Ph.D., Manager of Biological Research Laboratory at Gentium, will present a poster entitled "Modulation Of Heparanase Expression In Myeloma Tumor Cell Lines By Defibrotide: A Novel Mechanism Of Anti-Tumor Activity." (Poster session 23, Tumor Biology 21, Abstract #3100, Board #29)

Elevated heparanase expression in humans has been correlated with advanced progression and metastasis of many tumor types, including multiple myeloma (MM), where its presence may be particularly important because MM expresses high levels of heparin sulphate proteoglycan syndecan-1(CD138).

This in vitro study investigated Defibrotide's effectiveness in regulating the expression and activity of heparanase in two MM cell lines, U266 and RPMI 8226. The potential effect of Defibrotide to regulate heparanase gene expression was evaluated through real time polymerase chain reaction (RT-PCR) of cDNA prepared from the two lines of MM cells treated with Defibrotide or saline. Heparanase activity was measured in MM cells treated with Defibrotide (at 50, 100 and 150 (mu)g/ml) or saline for 24 hours by using a heparan-degrading enzyme kit. Results showed a significant down-regulation of heparanase gene expression by Defibrotide (at 150 (mu)/ml) after 24 hours of treatment (p less than 0.01) compared with saline.

Dr. Echart expounded upon these results, "These pre-clinical data suggest that Defibrotide not only has an effect in down-regulation of heparan
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... October 22, 2014 Investor-Edge has ... (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ - Angiotech ... medical device company, announced that,the two-year data ... Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will be presented ... The,two-year study examined the safety and efficacy ...
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
Cached Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2
(Date:10/25/2014)... TASC (Total Administrative Services Corporation), ... account management services, announces the release of four ... taxes, reduce administrative workload, and lessen liability. ... the efficient handling of complex, time-sensitive, and labor-consuming ... meets their goals and objectives. The four Suites ...
(Date:10/25/2014)... 2014 QueenBeeTickets.com has a variety of ... at affordable prices. Bob Seger & The Silver Bullet ... Nationwide Arena are going on sale October 25 and ... to browse the selection of tickets for Bob ... The famous singer is touring North America beginning next ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... News) -- A large influx of international aid is ... tens of thousands of deaths from the widening Ebola ... Using a specially designed mathematical model, the researchers ... just one densely populated county of hard-hit Liberia -- ... The researchers said that if international aid isn,t ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... and television that anger causes// the cardiac arrest of ... Yale University researchers have found out that sudden strong ... in the heart to twitch. This may be especially ... although seemingly healthy people my also be affected. ...
... Surrey, UK, had developed a new// drug that will boost ... is made of a compound called CX717, and it is ... This drug had showed effectiveness in increasing memeory, alertness, increasing ... who sleep less. ,The drug was given to ...
... had successfully created a new breed of mice that can ... for themselves.//, ,The reactive oxygen of the free radicals ... to poor health and even death. The new research may ... radical theory of ageing. ,The new mice created ...
... may lead to babies born with deformed prostate glands.//, ... out that prostate deformities can happen if the pregnant ... The pills contain ostrogen like chemiclasthat are alos present ... can cause prostate cancer or bladder diseases later in ...
... study that looked into the smoking habit of 6654 people ... that giving up smoking do causes weight gain, but the ... population under study was measured for effect of giving up ... when the age group was 20 to 44yrs, and was ...
... levels of blood marker for inflammation that can //lead to ... say that it may be good for the health of ... man will have a close family, a good group of ... the workplace, or the neighbors, or a religious organization. ...
Cached Medicine News:
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... layout is designed efficiently for maximum ... configured for maximum efficiency. It is ... It can be set-up in 15 ... mobile modality pad and it has ...
... is the largest and most experienced provider ... in the United States. Mobile laboratories serving ... daily basis, from one hospital to another ... area. Each mobile laboratory is fully equipped ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
Medicine Products: